IPO

Vesale Bioscience first-round funding

Vésale Bioscience raises a first round of 3M€

Posted on by

A first-round funding of 3 millions euros has been raised by Vésale Bioscience, the spin-out of the Vésale Pharma group which focuses on phagotherapy. In order to increase its financial resources and reach the stock market, the group has hired beLean.net Partner Guillaume de Viron as Head of Finance for the phage therapy division. Co-founder of Univercells, former CFO of MaSTHerCell,[…]

Guillaume CFO

Vésale Bioscience calls on beLean.net to prepare and accelerate its IPO

Posted on by

Vésale Bioscience has hired Guillaume de Viron, Partner at beLean.net, as Chief Financial Officer in order to accelerate its IPO. As CFO, Guillaume de Viron will contribute to Vésale Bioscience, which is currently preparing its fundraising (10+ million €) with the aim of accelerating the production and marketing of phages. Phage therapy is the use of phages,[…]